Carcinoma Of Breast News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Carcinoma of breast. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Carcinoma Of Breast Today - Breaking & Trending Today

Time to Revisit Distant Nodal Status in Breast Cancer Curability?


email article
Patients with breast cancer with distant lymph node metastases (DLNM) had similar survival to that of patients with regional node involvement and significantly better survival than those with non-DLNM distant spread, an analysis of 2,000 cases showed.
Women with DLNM at diagnosis had a 3-year breast cancer-specific survival (BCSS) rate of 64.54% versus 63.24% for patients with ipsilateral supraclavicular lymph node metastases (ISLM) and 41.20% for those with distant metastases. Overall survival (OS) at 3 years was also similar between ISLM and DLNM, but significantly worse for patients with non-DLNM distant metastases.
The results, derived from Surveillance, Epidemiology, and End Results (SEER) registry data, suggest that DLNM should be considered regional disease warranting aggressive treatment, reported Wenbin Zhou, MD, PhD, of Nanjing Medical University in China, and co-authors in ....

Wenbin Zhou , Yutian Zou , Charles Bankhead , Sun Yat Sen University Cancer Center , End Results , Nanjing Medical University , Medpage Today , Breast Cancer , Carcinoma Of Breast , Malignant Tumor Of Breast , சார்லஸ் வங்கித் தலை , சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம் , முடிவு முடிவுகள் , நான்ஜிங் மருத்துவ பல்கலைக்கழகம் , மார்பக புற்றுநோய் , புற்றுநோய் ஆஃப் மார்பக , வீரியம் மிக்கது கட்டி ஆஃப் மார்பக ,

New Targeted Therapies Show Promise in Cancer


A majority of patients with advanced
EGFR/HER2-mutant non-small cell lung cancer (NSCLC) benefited from treatment with the tyrosine kinase inhibitor (TKI) poziotinib, according to a preliminary clinical trial.
An efficacy cohort of 79 patients who received investigational poziotinib 16 mg as initial therapy had an objective response rate (ORR) of 28% and disease control rate (DCR) of 86%. Overall, 72 of 79 (91%) patients had tumor reduction averaging 25.5%. Initial data from an ongoing dosing evaluation involving previously treated and untreated patients showed objective responses in seven of 30 patients and stable disease in 11 treated with 16 mg, resulting in a DCR of 60%.
Tolerability remains a challenge, as a majority of patients in the dosing study required treatment interruptions and dose reductions, and about a third of patients treated with 16 mg had grade ≥3 adverse events, reported Adrian Sacher, MD, of Princess Margaret Cancer Center in Toronto, during th ....

Adrian Sacher , Charles Bankhead , Xiao Li Wei , Cancer Center , Princess Margaret Cancer Center , Sun Yat Sen University Cancer Center , European Society , Medical Oncology Targeted Anticancer Therapies , Mihaela Mates , Southeastern Ontario , Medpage Today , Carcinoma Of Breast , Neoplastic Disease , Mass Of Body Structure , Malignant Adenomatous Neoplasm , Malignant Tumor Of Breast , சார்லஸ் வங்கித் தலை , கிஷியஓ லி வெய் , புற்றுநோய் மையம் , ப்ரிந்ஸெஸ் மார்கரெட் புற்றுநோய் மையம் , சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம் , ஐரோப்பிய சமூகம் , மீஆெழ தோழர்கள் , தென்கிழக்கு ஆஂடேரியொ , புற்றுநோய் ஆஃப் மார்பக , நிறை ஆஃப் உடல் அமைப்பு ,